Topic Hub
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of injectable medications—including Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Trulicity—originally approved for type 2 diabetes and increasingly prescribed off-label for weight loss. Litigation alleges that manufacturers Novo Nordisk and Eli Lilly failed to warn patients about severe gastrointestinal adverse events including gastroparesis, intestinal pseudo-obstruction, ileus, and cyclic vomiting syndrome, as well as gallbladder disease, pancreatitis, and a rare optic-nerve condition called NAION. The class has tens of millions of U.S. users, and MDL 3094 in the Eastern District of Pennsylvania consolidates federal cases. Bellwether selection is underway. Science continues to evolve, with FDA label updates throughout 2024–2026 and additional adverse-event signals emerging in peer-reviewed literature.